Subclinical vascular inflammation in subjects with normal weight obesity and its association with body Fat: an 18 F-FDG-PET/CT study

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Kang, Shinae ^a   Kyung, Chanhee ^a   Park, Jong S ^a   Kim, Sohee ^a   Lee, Seung Pyo ^b   Kim, Min K ^a   Kim, Hye K ^a   Kim, Kyung R ^a   Jeon, Tae J ^a   Ahn, Chul W ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

18 F FDG PET CT; Atherosclerosis; Fat; Normal weight obesity; Vascular inflammation

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMAGE ANALYSIS; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; NORMAL WEIGHT OBESITY; OBESITY; PET-CT SCANNER; RISK FACTOR; SEX DIFFERENCE; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS; WAIST HIP RATIO;

ADIPOSE TISSUE; ADULT; ARTERITIS; BODY WEIGHT; CAROTID ARTERIES; CROSS-SECTIONAL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; OBESITY; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84899487096     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-70     Document Type: Article

References (52)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288(14):1723-1727. 10.1001/jama.288.14.1723, 12365955.
2. Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J 2011, 35(6):561-566. 10.4093/dmj.2011.35.6.561, 3253964, 22247896.
3. Eckel RH, Krauss RM. American Heart Association call to action: Obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998, 97(21):2099-2100. 10.1161/01.CIR.97.21.2099, 9626167.
4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24(4):683-689. 10.2337/diacare.24.4.683, 11315831.
5. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444(7121):875-880. 10.1038/nature05487, 17167476.
6. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National institutes of health. Obes Res 1998, 6(Suppl 2):51S-209S.
7. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, Allison TG, Batsis JA, Sert-Kuniyoshi FH, Lopez-Jimenez F. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond) 2008, 32(6):959-966. 10.1038/ijo.2008.11, 2877506, 18283284.
8. Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363(9403):157-163.
9. Goh VH, Tain CF, Tong TY, Mok HP, Wong MT. Are BMI and other anthropometric measures appropriate as indices for obesity? A study in an Asian population. J Lipid Res 2004, 45(10):1892-1898. 10.1194/jlr.M400159-JLR200, 15258201.
10. Low S, Chin MC, Ma S, Heng D, Deurenberg-Yap M. Rationale for redefining obesity in Asians. Ann Acad Med Singapore 2009, 38(1):66-69.
11. De Lorenzo A, Martinoli R, Vaia F, Di Renzo L. Normal weight obese (NWO) women: An evaluation of a candidate new syndrome. Nutr Metab Cardiovasc Dis 2006, 16(8):513-523. 10.1016/j.numecd.2005.10.010, 17126766.
12. De Lorenzo A, Del Gobbo V, Premrov MG, Bigioni M, Galvano F, Di Renzo L. Normal-weight obese syndrome: Early inflammation?. Am J Clin Nutr 2007, 85(1):40-45.
13. Kosmala W, Jedrzejuk D, Derzhko R, Przewlocka-Kosmala M, Mysiak A, Bednarek-Tupikowska G. Left ventricular function impairment in patients with normal-weight obesity: Contribution of abdominal fat deposition, profibrotic state, reduced insulin sensitivity, and proinflammatory activation. Circ Cardiovasc Imaging 2012, 5(3):349-356. 10.1161/CIRCIMAGING.111.969956, 22407472.
14. Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek J, Jensen MD, Parati G, Lopez-Jimenez F. Normal weight obesity: A risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 2010, 31(6):737-746. 10.1093/eurheartj/ehp487, 2838679, 19933515.
15. Marques-Vidal P, Pecoud A, Hayoz D, Paccaud F, Mooser V, Waeber G, Vollenweider P. Normal weight obesity: Relationship with lipids, glycaemic status, liver enzymes and inflammation. Nutr Metab Cardiovasc Dis 2010, 20(9):669-675. 10.1016/j.numecd.2009.06.001, 19748248.
16. Di Renzo L, Galvano F, Orlandi C, Bianchi A, Di Giacomo C, La Fauci L, Acquaviva R, De Lorenzo A. Oxidative stress in normal-weight obese syndrome. Obesity (Silver Spring) 2010, 18(11):2125-2130. 10.1038/oby.2010.50, 20339360.
17. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874. 10.1038/nature01323, 12490960.
18. Davies MJ. Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention. Eur Heart J 1995, 16(Suppl L):3-7.
19. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995, 92(3):657-671. 10.1161/01.CIR.92.3.657, 7634481.
20. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, Kudomi N, Shiomi M, Magata Y, Iida H, Saji H. (18)F-FDG accumulation in atherosclerotic plaques: Immunohistochemical and PET imaging study. J Nucl Med 2004, 45(7):1245-1250.
21. Leppanen O, Bjornheden T, Evaldsson M, Boren J, Wiklund O, Levin M. ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis 2006, 188(2):323-330. 10.1016/j.atherosclerosis.2005.11.017, 16405894.
22. Garedew A, Henderson SO, Moncada S. Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. Cell Death Differ 2010, 17(10):1540-1550. 10.1038/cdd.2010.27, 20339378.
23. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, Rafique A, Hargeaves R, Farkouh M, Fuster V, Fayad ZA. Atherosclerosis inflammation imaging with 18 F-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008, 49(6):871-878. 10.2967/jnumed.107.050294, 18483100.
24. Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 2005, 12(3):294-301. 10.1016/j.nuclcard.2005.03.002, 15944534.
25. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. In vivo 18 F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006, 48(9):1818-1824. 10.1016/j.jacc.2006.05.076, 17084256.
26. Bucerius J, Duivenvoorden R, Mani V, Moncrieff C, Rudd JH, Calcagno C, Machac J, Fuster V, Farkouh ME, Fayad ZA. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging 2011, 4(11):1195-1205. 10.1016/j.jcmg.2011.07.008, 22093271.
27. Park TG, Hong HR, Lee J, Kang HS. Lifestyle plus exercise intervention improves metabolic syndrome markers without change in adiponectin in obese girls. Ann Nutr Metab 2007, 51(3):197-203. 10.1159/000104137, 17587789.
28. Ryo M, Maeda K, Onda T, Katashima M, Okumiya A, Nishida M, Yamaguchi T, Funahashi T, Matsuzawa Y, Nakamura T, Shimomura I. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 2005, 28(2):451-453. 10.2337/diacare.28.2.451, 15677816.
29. Scharfetter H, Schlager T, Stollberger R, Felsberger R, Hutten H, Hinghofer-Szalkay H. Assessing abdominal fatness with local bioimpedance analysis: Basics and experimental findings. Int J Obes Relat Metab Disord 2001, 25(4):502-511. 10.1038/sj.ijo.0801556, 11319654.
30. Choi KM. Sarcopenia and sarcopenic obesity. Endocrinol Metab (Seoul) 2013, 28(2):86-89. 10.3803/EnM.2013.28.2.86, 3811714, 24396659.
31. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: Focus on muscle-derived interleukin-6. Physiol Rev 2008, 88(4):1379-1406. 10.1152/physrev.90100.2007, 18923185.
32. Choi HY, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Association of adiponectin, resistin, and vascular inflammation: Analysis with 18 F-fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol 2011, 31(4):944-949. 10.1161/ATVBAHA.110.220673, 21212400.
33. Bucerius J, Mani V, Moncrieff C, Rudd JH, Machac J, Fuster V, Farkouh ME, Fayad ZA. Impact of noninsulin-dependent type 2 diabetes on carotid wall 18 F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol 2012, 59(23):2080-2088. 10.1016/j.jacc.2011.11.069, 3392202, 22651864.
34. Wu YW, Kao HL, Huang CL, Chen MF, Lin LY, Wang YC, Lin YH, Lin HJ, Tzen KY, Yen RF, Chi YC, Huang PJ, Yang WS. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging 2012, 39(3):399-407. 10.1007/s00259-011-1994-7, 22109668.
35. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004, 89(6):2595-2600. 10.1210/jc.2004-0372, 15181029.
36. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999, 147(2):213-225. 10.1016/S0021-9150(99)00346-9, 10559506.
37. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96(9):939-949. 10.1161/01.RES.0000163635.62927.34, 15890981.
38. Yoo HJ, Kim S, Park MS, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Serum adipocyte fatty acid-binding protein is associated independently with vascular inflammation: Analysis with (18)F-fluorodeoxyglucose positron emission tomography. J Clin Endocrinol Metab 2011, 96(3):E488-492. 10.1210/jc.2010-1473, 21159847.
39. Di Renzo L, Bertoli A, Bigioni M, Del Gobbo V, Premrov MG, Calabrese V, Di Daniele N, De Lorenzo A. Body composition and -174G/C interleukin-6 promoter gene polymorphism: Association with progression of insulin resistance in normal weight obese syndrome. Curr Pharm Des 2008, 14(26):2699-2706. 10.2174/138161208786264061, 18991689.
40. Gupta AK, Johnson WD, Johannsen D, Ravussin E. Cardiovascular risk escalation with caloric excess: A prospective demonstration of the mechanics in healthy adults. Cardiovasc Diabetol 2013, 12:23. 10.1186/1475-2840-12-23, 3598491, 23347533.
41. Novo S, Peritore A, Trovato RL, Guarneri FP, Di Lisi D, Muratori I, Novo G. Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: A 20-year follow up. Cardiovasc Diabetol 2013, 12(1):155. 10.1186/1475-2840-12-155, 24152423.
42. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18 F]-fluorodeoxyglucose positron emission tomography. Circulation 2002, 105(23):2708-2711. 10.1161/01.CIR.0000020548.60110.76, 12057982.
43. Kai H. Novel non-invasive approach for visualizing inflamed atherosclerotic plaques using fluorodeoxyglucose-positron emission tomography. Geriatr Gerontol Int 2010, 10(1):1-8. 10.1111/j.1447-0594.2009.00564.x, 20102376.
44. Degnan AJ, Young VE, Gillard JH. Advances in noninvasive imaging for evaluating clinical risk and guiding therapy in carotid atherosclerosis. Expert Rev Cardiovasc Ther 2012, 10(1):37-53. 10.1586/erc.11.168, 22149525.
45. Chen W, Dilsizian V. Targeted PET/CT imaging of vulnerable atherosclerotic plaques: Microcalcification with sodium fluoride and inflammation with fluorodeoxyglucose. Curr Cardiol Rep 2013, 15(6):364.
46. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, Nikolaou K, Reiser MF, Bartenstein P, Hacker M. 18 F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009, 50(10):1611-1620. 10.2967/jnumed.109.065151, 19759117.
47. Lee SJ, On YK, Lee EJ, Choi JY, Kim BT, Lee KH. Reversal of vascular 18 F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med 2008, 49(8):1277-1282. 10.2967/jnumed.108.052233, 18632820.
48. Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, Mawatari K, Yasukawa H, Kaida H, Ishibashi M, Hayabuchi N, Harada H, Ikeda H, Yamagishi S, Imaizumi T. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011, 4(10):1110-1118. 10.1016/j.jcmg.2011.08.007, 21999871.
49. Ogawa M, Magata Y, Kato T, Hatano K, Ishino S, Mukai T, Shiomi M, Ito K, Saji H. Application of 18 F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med 2006, 47(11):1845-1850.
50. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006, 48(9):1825-1831. 10.1016/j.jacc.2006.03.069, 17084257.
51. Snijder MB, Kuyf BE, Deurenberg P. Effect of body build on the validity of predicted body fat from body mass index and bioelectrical impedance. Ann Nutr Metab 1999, 43(5):277-285. 10.1159/000012795, 10749027.
52. Fogelholm M, van Marken LW. Comparison of body composition methods: A literature analysis. Eur J Clin Nutr 1997, 51(8):495-503. 10.1038/sj.ejcn.1600448, 11248873.